ArticleNeoplasia (New York, N.Y.)2019
Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast Cancer.
Article in Neoplasia (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- A Machine Learning Model Based on Unsupervised Clustering Multihabitat to Predict the Pathological Grading of Meningiomas.BioMed research international · 2022Trial
- A FABulous approach to image human macrophages.European journal of nuclear medicine and molecular imaging · 2026Article
- Development of [111In]In-CHX-A″-DTPA-αCD68 for ImmunoSPECT to Image Murine Macrophages.Molecular pharmaceutics · 2026Article
- PET Imaging of System A Amino Acid Transport Detects Early Response to Immune Checkpoint Inhibitor Therapy in a Syngeneic Mouse Model.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Characterizing SSTR2 expression and modulation for targeted imaging and therapy in preclinical models of triple-negative breast cancer.Scientific reports · 2025Article
- Interlaboratory variability of HER2 fluorescence in situ hybridization testing in breast cancer: results of a multicenter proficiency-testing ring study in China.Diagnostic pathology · 2024Article
- Systematic evaluation of MRI-based characterization of tumor-associated vascular morphology and hemodynamics via a dynamic digital phantom.Journal of medical imaging (Bellingham, Wash.) · 2024Article
- Dual anti-HER2/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC.Scientific reports · 2024Article
- Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer.Breast cancer research : BCR · 2023Article
- Molecular and serological biomarkers to predict trastuzumab responsiveness in HER-2 positive breast cancer.Journal of medicine and life · 2023Article
- Molecular and functional imaging in cancer-targeted therapy: current applications and future directions.Signal transduction and targeted therapy · 2023Review
- ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Quantifying Tumor Heterogeneity via MRI Habitats to Characterize Microenvironmental Alterations in HER2+ Breast Cancer.Cancers · 2022Article
- Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer.Cancers · 2022Article
- Quantitative Image Analysis for Tissue Biomarker Use: A White Paper From the Digital Pathology Association.Applied immunohistochemistry & molecular morphology : AIMM · 2021Article
- Integrating transcriptomics and bulk time course data into a mathematical framework to describe and predict therapeutic resistance in cancer.Physical biology · 2020Article
- Article
- Relationship between histogram metrics of pharmacokinetic parameters of DCE-MRI and histological phenotype in breast cancer.Translational cancer research · 2020Article
- AI-based applications in hybrid imaging: how to build smart and truly multi-parametric decision models for radiomics.European journal of nuclear medicine and molecular imaging · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The purpose of this study is to investigate imaging and histology-based measurements of intratumoral heterogeneity to evaluate early treatment response to targeted therapy in a murine model of HER2+ breast cancer. BT474 tumor-bearing mice (N = 30) were treated with trastuzumab or saline and imaged longitudinally with either dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) or
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.